sibling donor will be needed to further improve the outcome.

References

1. Fischer A, Le Deist F, Hacein-Bey-Abina S, André-Schmutz I, Basile Gde S, de Villartay JP, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98–109.
2. Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr. 2009;155:834–40.
3. Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet. 2003;361:553–60.
4. Haddad E, Deist FL, Aucouturier P, Cavazzana-Calvo M, Blanche S, Basile GD, et al. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single-center study of 22 patients. Blood. 1999;94:2923–30.
5. Grunebaum E, Mazzolari E, Porta F, Dallera D, Atkinson A, Reid B, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA. 2006;295:508–18.
6. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105: 879–85.
7. Grubwieser P, Zimmermann B, Niederstätter H, Pavlic M, Steinlechner M, Parson W. Evaluation of an extended set of 15 candidate STR loci for paternity and kinship analysis in an Austrian population sample. Int J Leg Med. 2007;121:85–9.
8. Buckley RH. B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. J Allergy Clin Immunol. 2010;125:790–7.
9. Sanders JE, The Seattle Marrow Transplant Group. Effects of bone marrow transplantation on reproductive function. In: D'Angio GJ, Green DM, editors. Late effects of treatment for childhood cancer. New York: Wiley-Liss Publishing Ltd; 1992. p. 95–101.
10. Burroughs LM, Storb R, Leisenring WM, Pulsipher MA, Loken MR, Torgerson TR, et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transpl. 2007;40:633–42.
11. Hatanaka K, Fuji S, Ikegame K, Kato R, Wake A, Hidaka M, et al. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin. Int J Hematol. 2012;96:773–80.
12. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transpl. 2001;28:101–3.
13. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transpl. 2005;35:323–34.
14. Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, Japanese Cord Blood Bank Network, et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol. 2011;154: 363–72.
15. Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119:2949–55.
16. Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009; 374:912–20.
17. Buckley RH. The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2012; 129:597–604.

Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency

Kanegane H, Taneichi H, Nomura K, Wada T, Yachie A, Imai K, Ariga T, Santisteban I, Hershfield MS, Miyawaki T. Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.

Abstract: In this case report, we describe successful BMT with RIC in a patient with delayed-onset ADA deficiency. A three-yr-old Japanese boy was diagnosed with delayed-onset ADA deficiency because of recurrent bronchitis, bronchiectasia, and lymphopenia. In addition, autoimmune thyroiditis and neutropenia were present. At four yr of age, he underwent BMT with a RIC regimen, including busulfan and fludarabine, from an HLA-identical healthy sister. Engraftment after BMT was uneventful without GVHD. Decreased ADA levels in blood immediately increased following BMT, and the patient was disease-free 13 months after BMT. These results suggest that BMT with RIC may sufficiently restore immune regulation in delayed-onset ADA deficiency. A longer follow-up period is needed to confirm these observations.

Hirokazu Kanegane[1], Hiromichi Taneichi[1], Keiko Nomura[1], Taizo Wada[2], Akihiro Yachie[2], Kohsuke Imai[3], Tadashi Ariga[4], Ines Santisteban[5], Michael S. Hershfield[5] and Toshio Miyawaki[1]

[1]Department of Pediatrics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, [2]Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan, [3]Department of Community Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan, [4]Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan, [5]Department of Medicine and Biochemistry, Duke University Medical Center, Durham, NC, USA

Key words: adenosine deaminase deficiency – delayed-onset – bone marrow transplantation – reduced intensity conditioning

Hirokazu Kanegane, Department of Pediatrics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan
Tel.: 81 76 434 7313
Fax: 81 76 434 5029
E-mail: kanegane@med.u-toyama.ac.jp

ADA deficiency is a disorder of purine metabolism, which results in abnormalities in immune system development and function (1, 2). A majority of ADA deficiency cases indicate SCID

Abbreviation: ADA, adenosine deaminase; BMT, bone marrow transplantation; dAXP, deoxyadenosine nucleotides; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; PEG, polyethylene-glycosylated; PEG-ADA, polyethylene-glycosylated bovine ADA; RIC, reduced intensity conditioning; SCID, severe combined immunodeficiency; sjKRECs, signal joint κ-deleting recombination excision circles; TCR, T-cell receptor; TRECs, T-cell receptor excision circles.

during infancy; however, approximately 15% of ADA-deficient patients present with symptoms after infancy, which is referred to as a delayed- or late-onset type. Patients with delayed-onset ADA deficiency exhibit variable clinical symptoms, including bacterial infections and autoimmune manifestations. Allogeneic hematopoietic stem cell transplantation has long been a gold standard for the treatment of ADA-SCID; however, two other second-line options are available for ADA-SCID: Enzyme replacement therapy with PEG-ADA and hematopoietic stem cell gene therapy (3). The treatment of choice for delayed-onset ADA deficiency remains unclear because of

E29

the clinical variety. We report on a four-yr-old Japanese boy with delayed-onset ADA deficiency who underwent BMT with RIC from a HLA-identical healthy sister.

Case report

The patient was previously described (4). He is a boy who was admitted to our hospital at three yr of age for the investigation of recurrent infectious episodes. The patient did not have a neurological deficit. Laboratory data revealed neutropenia (600/μL), lymphocytopenia (580/μL), elevated C-reactive protein (7.43 mg/dL; normal, < 0.29 mg/dL) and elevated thyroid-stimulating hormone (133 μIU/mL; normal, 0.35–3.73 μIU/mL). Anti-neutrophil, anti-nuclear, anti-thyroglobulin, and anti-thyroid peroxidase antibodies were positive, indicating that autoimmune neutropenia and thyroiditis were present. Chest computed tomography disclosed bronchiectasia. An immunological study indicated hypergammaglobulinemia, but a low percentage of IgG2 subclass antibodies (5.41%; normal, 20–30%) was obtained. The lymphocyte subsets revealed an expansion of the CD45RO$^+$ (memory) populations of CD4$^+$ and CD8$^+$ T cells (74.8% and 39.6%, respectively) and an extremely reduced number of CD20$^+$ B cells (0.2%). TRECs and signal joint κ-deleting recombination excision circles (sjKRECs) were quantified by real-time PCR as previously described (5, 6) and were undetectable. Flow cytometry analysis of the TCR Vβ repertoire was performed as described previously (7), and the analysis revealed an extremely skewed pattern in CD8$^+$ T cells but not in CD4$^+$ T cells (Fig. 1). Therefore, the patient was clinically presumed to have a combined immunodeficiency with autoimmune manifestations, possibly indicating delayed-onset ADA deficiency. The ADA and dAXP levels in whole blood were measured using the extracts of dried blood spots (8). ADA was found to be decreased (1.0 μmol/h/mg protein; normal, 26.4 ± 10.0 μmol/h/mg protein), and %dAXP increased to 10.8% (normal < 1%). These data led to a diagnosis of ADA deficiency. An analysis of the ADA gene disclosed that the patient had compound heterozygous mutations (R156C and V177M). This genotype is compatible with delayed-onset ADA deficiency (9, 10).

The patient was treated with intravenous immunoglobulin replacement therapy, and oral administration of trimethoprim–sulfamethoxazole, acyclovir, and levothyroxine. He was nearly free from infections; however, his serum immunoglobulin levels gradually decreased. We iden-


Fig. 1. TCR Vβ repertoire in the CD4$^+$ and CD8$^+$ T cells that were analyzed pre-BMT and post-BMT on days 23 and 202. The TCR Vβ repertoire was analyzed by flow cytometry as previously described (7).

tified his healthy sister as an HLA-identical donor with no mutation in the ADA gene. At the age of four yr, the patient underwent BMT. He was treated with conditioning, which consisted of fludarabine (30 mg/m^2/day × six days, days −7 to −2) and intravenous reduced dose busulfan (4.4 mg/kg/day × two days, days −3 to −2). The patient received 6.9 × 10^8 nucleated cells/kg containing 3.1 × 10^6 CD34$^+$ cells/kg to achieve rapid engraftment. Cyclosporin A was used as GVHD prophylaxis. The post-transplant clinical course was without major complications, and no signs of acute GVHD were observed. The patient did not receive blood transfusion, and engraftments of neutrophils (> 500/μL) and thrombocytes (> 50 000/μL) were achieved at days 18 and 35, respectively. Cyclosporin A was stopped at day 46. The patient is currently well and has not suffered from any major infectious episodes. The patient received levothyroxine at a low dose; however, anti-thyroglobulin and anti-thyroid peroxidase antibodies became negative. The patient went off immunoglobulin replacement therapy 11 months after BMT.

Donor engraftment was evaluated by PCR amplification of the microsatellite marker D8S1179. Donor engraftment in granulocytes and B cells was observed at days 33 and 83, respectively. Complete donor engraftment in whole cells was achieved at day 323 (Table 1). Consistent with high chimerism, the patient exhibited a rapid increase in ADA activity and fast metabolic detoxification by day 83 (Table 2). In addition, immunological studies indicated rapid reconstitution of the lymphocyte subpopulation, and B cells increased to a normal level (305/μL;

E30

Table 1. Engraftment of donor cells in different cell lineages

	Donor cell engraftment (%)				
Post-BMT	Whole blood	Lymphocytes	T cells	B cells	Granulocytes
Day 12	8.5	NA	14.2	NA	0
Day 33	50.7	33.0	NA	NA	100.0
Day 83	80.5	NA	16.5	100.0	100.0
Day 323	>95.0	NA	>95.0	100.0	100.0

NA, not applicable.
Analyses of donor cell engraftment according to a chimerism assay in the peripheral blood of the patient at different time points after BMT.

Table 2. ADA activity in the whole blood of the patient

Samples	ADA (μmol/h/mg protein)	%dAXP
Pre-BMT	1.0	10.8
Day 25	8.7	1.1
Day 83	33.7	0.0
ADA-SCID	0.38 ± 0.5	50.3 ± 18.0
Normal levels	26.4 ± 10.0	<1

The data are from the analyses of the extracts of dried blood spots.

Table 3. TREC and sjKREC levels as measured by quantitative PCR in the peripheral blood at different time points

	Post-BMT Day 25	Day 83	Day 202	Normal values
TRECs	0	8.1×10^3	1.9×10^3	$3.5 \pm 2.8 \times 10^3$
sjKRECs	0	2.8×10^2	6.4×10^3	$4.8 \pm 0.6 \times 10^3$
RNaseP	4.5×10^4	1.6×10^5	2.0×10^5	

All of the units are copies/μg DNA. The RNaseP gene was amplified as an internal control. The normal values indicate the copy numbers of the age-matched controls (2–6 yr of age).

age-matched control, 278–922/μL) at day 97 (Fig. 2). TREC and sjKREC levels reached normal levels at days 83 and 202, respectively (Table 3). The CD45RO$^+$ (memory) populations of CD4$^+$ T cells decreased to a normal range (21.9 ± 4.4%) soon after BMT. Sequential TCR Vβ repertoire analyses revealed that the polyclonal patterns in CD4$^+$ T cells were consistent after BMT, and the extremely skewed pattern in CD8$^+$ T cells had improved by day 202 (Fig. 1).

Discussion

ADA-SCID is a complex immune and metabolic disorder that results from a lack of ADA, which is a key enzyme in purine metabolism. Patients with ADA-SCID have recurrent and severe infections, growth retardation and organ failure. The first treatment of choice is BMT from an HLA-identical sibling donor, if available, fol-

Fig. 2. Kinetics of the lymphocyte subpopulations in the patient.

lowed by treatments for other forms of SCID. Second-line treatments for patients without an HLA-identical donor include enzyme replacement therapy with PEG-ADA, matched unrelated donor hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy (3). Although the treatment strategy for ADA-SCID is well-established, treatment for delayed-onset ADA deficiency is not standardized because of the various clinical conditions. In this study, an HLA-identical healthy sibling donor was available, and we selected BMT from this donor to treat the patient. In cases of ADA-SCID, BMT from an HLA-identical donor is undertaken without a preparative conditioning regimen. The largest series of SCID patients from the European SCE-TIDE database included 475 patients (11). Of these patients, 51 patients with ADA-SCID had a three-yr survival rate of 81% for HLA-matched transplantation, but 29% for HLA-mismatched transplantation. A recently published cohort study demonstrated that hematopoietic stem cell transplantation in patients with SCID, including ADA deficiency, resulted in engraftment and long-term survival for the majority of patients with or without conditioning (12). However, transplantation without conditioning may result in partial donor engraftment, causing reduced immune reconstitution. Alternatively, hematopoietic stem cell gene therapy is effective for ADA-SCID patients who lack an HLA-identical sibling donor (13). Autologous CD34$^+$ bone marrow cells were transduced with a retroviral vector containing the ADA gene and infused into 10 patients with ADA-SCID after non-myeloablative conditioning. However, two patients have required enzyme replacement after gene therapy (14). ADA gene therapy has been performed in total 31 patients in Italy, the United Kingdom, and the United States. Twenty-one patients have been successful, whereas 10 patients have received enzyme replacement therapy (15). Recently, Cancrini et al. (16) described two ADA-SCID patients from the same family who both underwent BMT. One patient underwent BMT without conditioning, whereas

E31

the other patient was administered a RIC regimen (busulfan and fludarabine) following the failure of cord blood transplantation. Engraftment and immune reconstitution were compared in these patients. The patient who received conditioning exhibited stable mixed chimerism in all of the cell lineages, whereas the patient who underwent BMT without conditioning exhibited slow immune reconstitution, especially in B and myeloid cells. This observation indicated that the use of conditioning resulted in faster immunologic and metabolic reconstitution. In these patients, the immune reconstitution of B and myeloid cells was slower than that of T and NK cells. Interestingly, the reconstitution of myeloid and B cells appeared earlier than that of T cells in our patient. The patient with delayed-onset ADA deficiency had a substantial number of T cells but no B cells before BMT, and the generation of new T cells may take longer than B cells.

Patients with delayed-onset ADA deficiency often have chronic pulmonary insufficiency and autoimmune phenomena, including cytopenia and anti-thyroid antibodies, as observed in our patient. Patients with a delayed- or late-onset type may survive undiagnosed in the first decade of life or beyond; however, the longer the disease goes undiagnosed, the more the immune function deteriorates. The serum immunoglobulin levels of our patient gradually decreased from the point of diagnosis. Our patient had a substantial number of T cells; however, TRECs were undetectable in his peripheral blood. Therefore, we decided that the patient would receive BMT preceded by a RIC regimen, including busulfan and fludarabine. The use of RIC in BMT from an HLA-identical donor in this patient resulted in rapid and complete immune and metabolic reconstitution, and there was no treatment-related toxicity. However, a longer follow-up period is required to confirm these observations. If patients have an HLA-identical sibling donor, BMT with a RIC regimen may be the treatment of choice in patients with delayed-onset ADA deficiency.

Acknowledgments

References

1. HERSHFIELD MS. Combined immune deficiency due to purine enzyme defects. In: STIEHM ER, OCHS HD, WINKELSTEIN JA, eds. Immunologic Disorders in Infants and Children. Philadelphia, PA: WB Saunders, 2004: pp. 480–504.
2. HIRSHHORN R, CANDOTTI F. Immunodeficiency disease due to defects of purine metabolism. In: OCHS HD, SMITH CIE, PUCK JM, eds. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, NY: Oxford University Press, 2007: pp. 169–196.
3. GASPAR HB, AIUTI A, PORTA F, CANDOTTI F, HERSHFIELD MS, NOTARANGELO LD. How I treat ADA deficiency. Blood 2009: 114: 3524–3532.
4. NAKAOKA H, KANEGANE H, TANEICHI H, et al. Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis. Int J Hematol 2012: 95: 692–696.
5. MORINISHI Y, IMAI K, NAKAGAWA N, et al. Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal Guthrie cards. J Pediatr 2009: 155: 829–833.
6. NAKAGAWA N, IMAI K, KANEGANE H, et al. Quantification of κ-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol 2011: 128: 223–225.e2.
7. TOGA A, WADA T, SAKAKIBARA Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein–Barr virus (EBV)-infected CD8 + T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis 2010: 201: 1923–1932.
8. ARRENDONDO-VEGA FX, SANTISTEBAN I, RICHARD E, et al. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: Decline in revertant T lymphocytes during enzyme replacement therapy. Blood 2002: 99: 1005–1013.
9. ARRENDONDO-VEGA FX, SANTISTEBAN I, DANIELS S, TOUTAIN S, HERSHFIELD MS. Adenosine deaminase deficiency: Genotype-phenotype correlations based expressed activity of 29 mutant alleles. Am J Hum Genet 1998: 63: 1049–1059.
10. HERSHFIELD MS. Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr Opin Immunol 2003: 15: 571–577.
11. ANTOINE C, MULLER S, CANT A, et al. Long-term survival and transplantation of haematopoietic stem cells for immunodeficiencies: Report of the European experience 1968–99. Lancet 2003: 361: 553–560.
12. PATEL NC, CHINEN J, ROSENBLATT HM, et al. Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without pre-conditioning. J Allergy Clin Immunol 2009: 124: 1062–1069.
13. AIUTI A, CATTANEO F, GALIMBERTI S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009: 360: 447–458.
14. AIUTI A, RONCARROLO MG. Ten years of gene therapy for primary immunodeficiencies. Hematology Am Soc Hematol Educ Program 2009: 682–689.
15. FISCHER A, HACEIN-BEY-ABINA S, CAVAZZANA-CALVO M. Gene therapy for primary adaptive immune deficiencies. J Allergy Clin Immunol 2011: 127: 1356–1359.
16. CANCRINI C, FERRUA F, SCARSELLI A, et al. Role of reduced intensity conditioning in T-cell and B-cell immune reconstitution after HLA-identical bone marrow transplantation in ADA-SCID. Haematologica 2010: 95: 1778–1782.

E32

A Novel Small Compound SH-2251 Suppresses Th2 Cell-Dependent Airway Inflammation through Selective Modulation of Chromatin Status at the *Il5* Gene Locus

Junpei Suzuki[1,2], Makoto Kuwahara[2], Soichi Tofukuji[2,3], Masashi Imamura[4], Fuminori Kato[4], Toshinori Nakayama[3,5], Osamu Ohara[2], Masakatsu Yamashita[2,6,7]*

1 Department of Pharmacogenomics, Graduate School of Pharmaceutical Science, Chiba University, Chuo-ku, Chiba, Japan, 2 Department of Human Genome Research, Kazusa DNA Research Institute, Kisarazu, Chiba, Japan, 3 Department of Immunology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan, 4 Central Research Institute, Ishihara Sangyo Kaisha, Ltd., Kusatsu, Shiga, Japan, 5 CREST, Japan Science and Technology Agency, Chuo-ku, Chiba, Japan, 6 Department of Immunology, Graduate School of Medicine, Ehime University, Toon, Ehime, Japan, 7 PRESTO, Japan Science and Technology Agency, Toon, Ehime, Japan

Abstract

IL-5 is a key cytokine that plays an important role in the development of pathological conditions in allergic inflammation. Identifying strategies to inhibit IL-5 production is important in order to establish new therapies for treating allergic inflammation. We found that SH-2251, a novel thioamide-related small compound, selectively inhibits the differentiation of IL-5-producing Th2 cells. SH-2251 inhibited the induction of active histone marks at the *Il5* gene locus during Th2 cell differentiation. The recruitment of RNA polymerase II, and following expression of the Th2 cell-specific intergenic transcripts around the *Il5* gene locus was also inhibited. Furthermore, Th2 cell-dependent airway inflammation in mice was suppressed by the oral administration of SH-2251. Gfi1, a transcriptional repressor, was identified as a downstream target molecule of SH-2251 using a DNA microarray analysis. The Gfi1 expression dramatically decreased in SH-2251-treated Th2 cells, and the SH-2251-mediated inhibition of IL-5-producing Th2 cell differentiation was restored by transduction of *Gfi1*. Therefore, our study unearthed SH-2251 as a novel therapeutic candidate for allergic inflammation that selectively inhibits active histone marks at the *Il5* gene locus.

Introduction

Asthma is a complex chronic inflammatory disease characterized by airway inflammation and hyperresponsiveness obstruction that affects approximately 300 million individuals worldwide [1]. A large number of clinical studies and animal experimental models support a central role of antigen-specific Th2 cells in the pathological responses of atopic asthma [2,3]. In particular, antigen-specific effector and memory Th2 cells appear to play an important role in initiating allergic inflammatory status in the early stage of atopic asthma. Although eliminating Th2 cells and/or inhibiting Th2 cell functions at the early stage of atopic asthma may lead to complete remission, strategies for modulating Th2 cell numbers and/or functions have not been established.

IL-5 is a hematopoietic cytokine that exerts important effects on eosinophils and basophils. IL-5 induces differentiation and maturation of eosinophils in bone marrow, migration to tissue sites and prevention of eosinophil apoptosis [4] [5]. IL-5 also plays a role in the development, metabolism, and function of basophils [6]. Eosinophilic inflammation is a hallmark of asthma that correlates with bronchial hyperresponsiveness and disease severity.

In an asthma model, IL-5-deficient mice did not display eosinophilia, airway hyperreactivity or pulmonary injury, in contrast to that observed in control mice [7]. Treatment of mice with anti-IL-5 mAb also results in decreases in eosinophilic inflammation that are associated with reduced reactivity of methacholine. Therefore, IL-5 is a therapeutic target for allergic inflammation as well as hypereosinophilic syndrome.

Th2 cells produce IL-4, IL-5 and IL-13, and have been shown to play a crucial role in IgE production and eosinophil recruitment. Th2 cells are involved in clearance of extracellular parasites and also promote pathogenic responses associated with allergic inflammation. In peripheral CD4 T cells, IL-4-mediated activation of the transcription factor STAT6 induces the expression of *Gata3* mRNA, which drives Th2 cell differentiation [8]. GATA-3 binds to various regulatory regions on the Th2 cytokine gene loci and induces chromatin remodeling [9,10,11]. In addition, GATA-3 binds to the *Il5* promoter and acts as a transcriptional factor for IL-5 [12].

In addition to Th2 cells, a large number of cell types produce IL-5, including eosinophils [5] [4], natural killer (NK)T cells [13], nuocytes [14], natural helper (NH) cells [15] and IL-5-producing

innate cells [16]. Recently, the IL-33-induced production of IL-5 from innate cells was reported. IL-33-mediated production of IL-5 plays critical roles in lung eosinophil regulation [16], lung inflammation [17] and protease allergen-induced airway inflammation [18]. In addition, the IL-33/IL-5 signaling pathway plays a crucial role in the disease pathogenesis of severe asthma that is resistant to high doses of inhaled corticosteroids but responsive to systemic corticosteroids and anti-IL-5 therapy [19].

Gfi1 is a DNA binding transcriptional repressor that plays important roles in several hematopoietic cells [20]. Gfi1 exerts its role as a transcriptional repressor by interacting with a number of histone modification enzyme including LSD-1/CoRest, G9a and HDACs [21,22,23]. It is well established that Gfi1 regulates the development of Th cell subsets. Zu et al. demonstrated that Gfi1 regulates Th2 cell expansion via enhancement of Stat5 activity [24]. However, the forced expression of constitutively active Stat5 fails to restore Th2 cell development in *Gfi1*-difficient CD4 T cells, possibly because Gfi1 might also play additional roles in Th2 cell development that are independent of Stat5. We previously reported that the expression level of Gata3 proteins and generation of IL-5-producing Th2 cells are severely impaired in *Gfi1*-deficient CD4 T cells [25]. The transduction of Gata3 into *Gfi1*-deficient Th2 cells partially restores the development of IL-5-producing Th2 cells, thus indicating that Gfi1 controls IL-5-producing Th2 cell generation in part through regulation of the Gata3 protein expression.

SH-2251, a thioamide-related compound, was originally synthesized as an inhibitor of IL-5 production. However, the molecular mechanisms by which SH-2251 inhibits IL-5 production and the effects of SH-2251 on Th2 cell differentiation remain to be elucidated. We herein investigated the effects of SH-2251 on Th2 cell differentiation and demonstrated that SH-2251 negatively regulates IL-5-producing Th2 cell differentiation and chromatin remodeling at the *Il5* gene locus. Furthermore, we demonstrated that Th2 cell-dependent allergic airway inflammation is suppressed by oral administration of SH-2251. A DNA microarray analysis revealed that SH-2251 inhibits the differentiation of IL-5-producing Th2 cells via repression of the Gfi1 expression. Therefore, SH-2251 belongs to a unique class of inhibitors of Th2-dependent immune responses that modulate chromatin remodeling at the *Il5* gene locus and the subsequent differentiation of IL-5 producing Th2 cells.

Results

SH-2251 selectively inhibits the generation of IL-5-producing Th2 cells

SH-2251 (**Fig. 1A**), a novel thioamide-related compound, was originally synthesized as an inhibitor of IL-5 production. However, the effects of SH-2251 on Th2 cell differentiation were not determined. To assess the effects of SH-2251 on Th2 cell differentiation, naïve CD4 T cells were purified and cultured under Th2-conditions in the presence or absence of SH-2251 for five days, and the ability to produce Th2 cytokines was determined using intracellular staining. As shown in **Fig. 1B**, the generation of IL-5-producing Th2 cells decreased in the SH-2251-treated cultures, whereas the number of IL-4- and IL-13-producing cells slightly increased. The selective reduction of IL-5 production was also confirmed on ELISA (**Fig. 1C**). The generation of IFN-γ-producing Th1 cells and IL-17A-producing Th17 cells was moderately decreased, while development of IL-9-producing Th9 cells was augmented by treatment with SH-2251 (**Fig. S1A–C in File S1**). To determine the optimal concentration for inhibition of IL-5-producing Th2 cell differentiation, naïve CD4 T

cells were cultured under Th2-conditions in the presence of the indicated concentrations of SH-2251. Inhibitory effects were observed at the 10 nM concentration of SH-2251 and peaked at 100 nM (**Fig. 1D**). Dose-dependent effects of SH-2251 on the inhibition of IL-5 induction were also confirmed using ELISA (**Fig. 1E**). The production of IL-4 and IL-13 was not impaired (**Fig. 1E**). These results indicate that SH-2251 inhibits IL-5-producing Th2 cell differentiation without inhibiting the generation of IL-4- or IL-13-producing Th2 cells.

SH-2251 selectively inhibits induction of active histone modifications at the *Il5* gene locus during Th2 cell differentiation

Changes in histone modification are a marker of chromatin remodeling [26,27]. During Th2 cell differentiation, active histone modifications including histones H3K4me2/3, H3K9ac and H3K27ac, are induced at Th2 cytokine gene loci [9] [11]. We examined the effect of SH-2251 on the induction of active histone modifications during Th2 cell differentiation. As shown in **Fig. 2A**, the levels of active histone modifications such as those of H3K4me3, H3K9ac and H3K27ac at the *Il5* promoter were reduced by treatment with SH-2251 in a dose-dependent manner. The levels of H3K9ac and H3K27ac, but not H3K4me3, at the Rad50 promoter decreased (**Fig. 2A**). In sharp contrast, the active histone modifications at the *Il4* and *Il13* promoters were unaffected by SH-2251 treatment (**Fig. 2A**). To confirm the selective effects of SH-2251 on the levels of active histone modifications around the *Il5* gene locus, we performed ChIP-sequencing with anti-histone H3K4me3 pAb and H3K27ac pAb. Decreased levels of H3K4me3 and H3K27ac were detected from the 5′ region of the *Rad50* gene to the *Il5* gene, while reduced levels were spread over the down stream region of the *Il5* gene locus in the SH2251-treated Th2 cells (**Fig. 2B and Fig. S2 in File S1**). Reduction in the levels of H3K4me3 and H3K27ac around the *Il5* gene locus in the SH-2251-treated Th2 cells were confirmed using a manual ChIP analysis (**Fig. 2C**). Changes in other histone modifications, including H3K4me2, H3K9me2, H3K36me3 and H3K9ac, around the *Il5* gene locus were also determined with a manual ChIP analysis. The levels of active histone marks such as those of H3K4me2, H3K36me3 and H3K9ac around the *Il5* gene locus were decreased in the SH-2251-treated Th2 cells (**Fig. 2C**). The level of H3K9me2 was not affected by treatment with SH-2251 (**Fig. 2C**). No obvious signals were detected with an anti-H3K27me3 pAb (data not shown). Finally, we assessed the effects of SH-2251 treatment on the recruitment of RNA polymerase II (PolII) and subsequent intergenic transcription around the *Il5* gene locus. SH-2251 reduced the recruitment of polII (**Fig. 2D upper panel**) and the level of transcription (**Fig. 2D lower panel**) in the Th2 cells. These results suggest that SH-2251 blocks the generation of IL-5-producing Th2 cells, presumably by inhibiting chromatin remodeling at the *Il5* gene locus.

Th2-dependent airway inflammation is attenuated by the administration of SH-2251

We next investigated the effects of the oral administration of SH-2251 (10 mg/kg) in mice model of airway inflammation. BALB/c mice were immunized with OVA absorbed by alum, then challenged with OVA intranasally. We observed decreases in the infiltration of inflammatory cells, including eosinophils, in the bronchoalveolar lavage (BAL) fluid of the OVA-immunized SH-2251-treated mice in comparison to that observed in the vehicle-administrated control group (**Fig. 3A**). The expressions of *Il4*, *Il5*

A

Figure 1. SH-2251 inhibits the generation of IL-5-producing Th2 cells. (A), The chemical structure of SH-2251. (B), Naïve CD4 T cells were cultured under Th2-conditions in the presence or absence of SH-2251 (100 nM) for five days. The cells were restimulated with an immobilized anti-TCR-β mAb for six hours, and the intracellular staining profiles of IL-4/IFN-γ (upper panel) and IL-5/IL-13 (lower panel) were determined using intracellular staining, respectively. The percentages of each quadrant are indicated. The average percentages of the generated cytokine-producing cells of three independent experiments are also shown with the standard deviation (right). (C), Cytokine production induced by the SH-2251-treated Th2 cells shown in panel (B) was determined with ELISA. (D), Naïve CD4 T cells were cultured under Th2-conditions in the presence of the indicated concentrations of SH-2251 for five days. The intracellular profiles were determined as described (B). The average percentage of three independent experiments of the generated cytokine-producing cells are also shown with the standard deviation (E), Cytokine production by the SH-2251-treated Th2 cells shown in panel (D) was determined with ELISA. *P<0.05 and **P<0.01 (Student's t-test). Three independent experiments (C and E) were performed with similar results.
doi:10.1371/journal.pone.0061785.g001

and *Il13* mRNA in the BAL fluid cells were also very low, whereas the reduction of *Ifnγ* was marginal in the SH-2251-administered group (**Fig. 3B**). A reduced expression of *eosinophil peroxidase (Epo)* mRNA in the BAL fluid cells of the SH-2251-administered mice supported decreased infiltration of eosinophils (**Fig. S3A in File S1**). We prepared CD4 T cells from the lungs of OVA-challenged mice to confirm the effects of SH-2251 administration. The expressions of mRNA for Th2 cytokines in the CD4 T cells purified from the lung tissue were reduced in the SH-2251-treated mice (**Fig. 3C**). The purified CD4 T cells were further stimulated with immobilized anti-TCR-β mAb for 48 hours *in vitro*, and the production of cytokines was determined using ELISA. The level of IL-5 production was low in the CD4 T cells obtained from the SH-2251-administered mice in comparison to that observed in the CD4 T cells obtained from the vehicle-treated mice (**Fig. 3D**). In addition, the productions of IL-4 and IL-13 were also significantly decreased in the lung CD4 T cells obtained from the SH-2251-treated mice, whereas the IFN-γ production was increased

(**Fig. 3D**). The number of mononuclear cells infiltrating the peribronchiolar regions of the lungs was reduced by SH-2251 administration (**Fig. 3E**). Both mucus hyper-production and goblet cell metaplasia, as assessed with PAS staining, were lower in the bronchioles of the SH-2251-administrered mice compared to that observed in bronchioles of the vehicle-treated control mice (**Fig. 3F**). The serum levels of anti-OVA immunoglobulin were unaffected by the administration of SH-2251 (**Fig. S3B in File S1**). These results indicate that the oral administration of SH-2251 can suppress Th2 cell-mediated allergic airway inflammation.

The expression and functions of Gata3 are not influenced by SH-2251 treatment

Gata3 plays an essential role in the induction of chromatin remodeling at the Th2 cytokine gene locus following Th2 cell differentiation [9] [10] [11]. In addition, Gata3 induces the transcriptional activation of the *Il5* gene [12]. In this study,

101

Figure 2. The induction of active histone marks at the *Il5* gene locus is inhibited by SH-2251. (A), Naïve CD4 T cells were cultured under Th2-conditions for five days in the presence of the indicated concentration of SH-2251, and a ChIP assay was performed with the indicated antibodies. The relative intensity (/Input) is shown with the standard deviation. **(B)**, The global patterns of histones H3K4me3 and H3K27ac at the Th2 cytokine gene loci were determined using ChIP-sequencing. **(C)**, The indicated histone modification status around the *Il5* gene locus in the SH-2251-treated Th2 cells was determined using a manual ChIP assay. The relative intensity (/Input) is shown with the standard deviation. **(D)**, Recruitment of RNA polymerase II around the *Il5* gene locus (upper panel) was determined using a manual ChIP assay. The relative intensity (/Input) is shown with the standard deviation. The transcripts around the *Il5* gene in the SH-2251-treated Th2 cells (lower panel) were determined using quantitative RT-PCR. The relative intensity (/Hprt) is shown with the standard deviation. Four independent experiments (A, C and D) were performed with similar results. doi:10.1371/journal.pone.0061785.g002

treatment with SH-2251 showed no effects on the Gata3 mRNA (**Fig. 4A**) or protein (**Fig. 4B**) expressions in the Th2 cells. Next, we wanted to determine the effects of SH-2251 on binding of Gata3 at the Th2 cytokine gene locus. The binding of Gata3 throughout the Th2 cytokine gene locus was determined comprehensively using ChIP-sequencing with an anti-Gata3 pAb. Gata3 has been reported to bind to the V$_A$ enhancer [28], *Il4* intron2 [29], CGRE [30], Th2 LCR [31,32] and *Il5* promoter regions [33] in Th2 cells. The binding of Gata3 at these regions was confirmed with ChIP-sequencing (**Fig. 4C upper panel**). In addition, we newly identified several Gata3 binding genomic regions around the *Il5* gene locus (**Fig 4C lower panel**: #1~#7). The binding of Gata3 at these regions in the Th2 cells was not inhibited by SH-2251 treatment (**Fig. 4D**). Finally, we examined whether SH-2251 can inhibit the Gata3-induced transcriptional activation of the *Il5* promoter using a reporter gene analysis. As indicated in **Fig. 4E**, SH-2251 showed only marginal effects on the Gata3-dependent activation of the *Il5* promoter. These data suggest that Gata3 is unlikely to be a target

of SH-2251 in the inhibition of IL-5-producing Th2 cell development.

A decreased expression of Gfi1 is involved in the SH-2251-mediated inhibition of IL-5-producing Th2 cell generation

We conducted a DNA microarray analysis to identify the target gene(s) that are involved in the SH-2251-mediated inhibition of IL-5-producing Th2 cell generation. We found that the expression of *Gfi1* mRNA was dramatically decreased in the SH-2251-treated Th2 cells (**Fig. 5A**). A reduction in the Gfi1 protein expression was also induced by SH-2251-treatment (**Fig. 5B**). To assess the molecular mechanisms by which SH-2251 inhibits the *Gfi1* expression, the histone modifications present at the *Gfi1* gene locus were determined using ChIP-sequencing with an anti-histone H3K27ac pAb or an H3K4me3 pAb, respectively. As shown in **Fig. 5C lower panel**, a striking reduction in the histone H3K27ac level at the *Gfi1* gene locus in the SH-2251-treated Th2 cells was detected. The level of H3K4me3 at the *Gfi1* gene locus was moderately decreased (**Fig. 5C upper panel**). A

Figure 3. OVA-induced airway inflammation is attenuated by oral administration of SH-2251. (A), Decreased infiltration of eosinophils in the BAL fluid of asthmatic SH-2251-administered mice. The absolute numbers of eosinophils (Eos.), neutrophils (Neu.), lymphocytes (Lym.) and macrophages (Mac.) in the BAL fluid are shown with standard deviations (n = 5 per group). *P<0.01 and **P<0.001 by ANOVA and the Bonferroni-test. (B), Quantitative RT-PCR of *Il4, Il5* and *Il13* mRNA in the BAL fluid cells of vehicle and SH-2251-administered mice. (C), Quantitative RT-PCR of *Il4, Il5, Il13* and *Ifnγ* mRNA in the lung CD4 T cells of vehicle and SH-2251-administered mice. (n = 5 per group). (D), Cytokine production from lung CD4 T cells of vehicle and SH-2251-administered mice stimulated *in vitro*. The lung CD4 T cells were stimulated with immobilized anti-TCR-β mAb for 48 hours and the concentrations of cytokines in the culture supernatants were determined using ELISA. The lungs were fixed and stained with hematoxylin and eosin (E, left) or periodic acid-Schiff reagent (F). The scale bars represent 500 μm. The numbers of infiltrated leukocytes in the peribronchiolar regions are shown (mean cell numbers/mm²) (E, right). Three independent experiments were performed with similar results. Student's t-test was used for the statistical analyses. *P<0.05 and **P<0.01 (B, C, D and E)
doi:10.1371/journal.pone.0061785.g003

dose-dependent inhibition of the H3K4me3 and H3K27ac levels at the *Gfi1* gene locus induced by SH-2251 was confirmed using a manual ChIP assay (**Fig. 5D**). The level of H3K9ac at the *Gfi1* gene locus was also inhibited by SH-2251 treatment (**Fig. 5D**). As indicated in **Fig. S4 in File S1**, the levels of histone H3K27ac and H3K4me3 at the *Gfi1* gene locus were higher in the Th2 cells than that in the naïve CD4 T cells. The levels of histone H3K27ac and H3K4me3 modifications in the SH-2251-treated Th2 cells were almost comparable to those in the naïve CD4 T cells (**Fig. S4 in File S1**), thus indicating that SH-2251 inhibits the induction of the histone H3K27ac at the *Gfi1* locus during Th2 cell differentiation.

Transduction of *Gfi1* into SH-2251-treated Th2 cells restores IL-5 production

To elucidate the role of Gfi1 reduction in the SH-2251-mediated inhibition of IL-5-producing Th2 cell differentiation, we transduced *Gfi1* into SH-2251-treated Th2 cells using retrovirus

vectors and measured the IL-5 production ability. As shown in **Fig. 6A**, the transduction of *Gfi1* into the SH-2251-treated Th2 cells partially restored the generation of IL-5 producing Th2 cells. The production levels of IL-5 in the SH-2251-treated Th2 cells were completely restored by the transduction of *Gfi1* (**Fig. 6B**). The production of IL-4 and IL-13 in the *Gfi1*-transduced Th2 cells was not altered in comparison to that observed in the *Mock*-transduced SH-2251-treated Th2 cells (**Fig. 6B**). The levels of histone H3K4me3 and H3K27ac around the *Il5* gene locus were also ameliorated in the *Gfi1*-transduced SH-2251-treated Th2 cells (**Fig. 6C**). Histones H3K4me3, H3K9ac and H3K27ac at the *Il4* and *Il13* promoters were not influenced by the transduction of Gfi1 (**Fig. S5 in File S1**). To examine the molecular mechanisms by which Gfi1 controls the histone modification status at the *Il5* gene locus, the binding of Gfi1 around the *Il5* gene locus was determined using a ChIP-sequence analysis with an anti-Gfi1 pAb. Low, but reproducible binding of Gfi1 was detected around the *Il5* gene locus in the Th2 cells (**Fig. 6D**). The binding of Gfi1 around

Figure 4. The expression and functions of Gata3 are not impaired by treatment with SH-2251. (A), The mRNA expression of Gata3 in the SH-2251-trearted Th2 cells was determined using quantitative RT-PCR. The relative intensity (/Hprt) is shown with the standard deviation. **(B)**, The protein expression level of Gata3 was determined with immunoblotting. The nuclear (Gata3) and cytoplasmic (α-Tubulin) lysates with a three fold serial dilution were used. Three independent experiments (A and B) were performed with similar results. **(C)**, The global patterns of Gata3 binding at the Th2 cytokine gene loci (upper panel) and the Il5 gene locus (lower panel) were determined using ChIP-sequencing with an anti-Gata3 pAb. The locations of PCR primer pairs (triangle) used in a manual ChIP assay are also listed. **(D)**, The binding of Gata3 around the Il5 gene locus (left) panel and the V_A enhancer (V_A E) and intronic enhancer (IE) regions of the Il4 gene locus (right panel) in the SH-2251-treated Th2 cells was determined using a manual ChIP assay. The relative intensity (/Input) is shown with the standard deviation. Three independent experiments were performed with similar results. **(E)**, The effects of SH-2251 on the Gata3-dependent transcriptional activation of the Il5 promoter were determined using a Dual luciferase assay. The mean and standard deviation of the relative luciferase activity of three different experiments are shown. Stim: PMA (30 ng/ml)+dbcAMP (100 μM). Four independent experiments (A, B, D and E) were performed with similar results.
doi:10.1371/journal.pone.0061785.g004

the Il5 gene locus in the Th2 cells decreased by the treatment with SH-2251 (**Fig. 6E**). These results suggest that SH-2251 inhibits the chromatin remodeling at the Il5 gene locus and subsequent IL-5-producing Th2 cell differentiation in part by attenuating the Gfi1 expression.

Discussion

We herein demonstrated that a thioamide-related small chemical compound, SH-2251, inhibits the differentiation of IL-5-producing Th2 cells by attenuating the Gfi1 expression. Treatment of developing Th2 cells with SH-2251 reduced the generation of IL-5-producing Th2 cells and the expression of Gfi1. SH-2251 also inhibited induction of active histone modifications at the Il5 gene locus as well as the Gfi1 locus in developing Th2 cells. We found that Gfi1 binds to several genomic regions around the Il5 gene locus in Th2 cells, which was reduced by treatment with SH-2251. We previously reported that the induction of histones H3K4me3 and H3K9/14ac at the Il5 gene locus and subsequent IL-5-producing Th2 cell differentiation are impaired in Gfi1-

deficient CD4 T cells [25]. In addition, in this study, retrovirus vector-mediated transduction of Gfi1 into SH-2251-treated developing Th2 cells restored the levels of active histone modifications at the Il5 gene locus, and subsequent generation of IL-5-producing Th2 cells. Therefore, the Gfi1-Il5 axis is a target for SH2251-mediated inhibition of IL-5-producing Th2 cell differentiation.

Clinical trials of the anti-IL-5 mAb have demonstrated therapeutic benefits across a spectrum of eosinophil-related disorders [34]. Recently, a result of a clinical trial of a humanized anti-IL-5 mAb (Mepolizumab) was reported [35]. Although no changes in airway hyperresponsiveness were noted, reductions in blood/sputum eosinophilia and the number of asthma exacerbations occurring during the year were reported. In addition, reductions in airway wall thickness were also observed. These results indicate that the neutralization of IL-5 might have a positive impact on airway remodeling. We demonstrated the inhibitory effects of SH-2251 on the generation of IL-5-producing Th2 cells and IL-5 production. Furthermore, the oral administration of SH-2251 was found to suppress OVA-induced allergic airway inflammation in a mice model. These data suggest that SH-

Figure 5. Gfi1 is a downstream target of SH-2251. (A), A decreased *Gfi1* mRNA expression in the SH-2251 treated Th2 cells. The expression of *Gfi1* was determined with quantitative RT-PCR. The relative intensity (/*Hprt*) is shown with the standard deviation. **(B)**, A decreased level of Gfi1 proteins was detected with immunoblotting. The nuclear (Gfi1) and cytoplasmic (α-Tubulin) lysates with a three fold serial dilution were used. **(C)**, The global patterns of the histone H3K4me3 and H3K27ac levels at the *Gfi1* gene locus were determined using ChIP-sequencing. The locations of PCR primer pairs (triangle) used in a manual ChIP assay are also listed. **(D)**, Manual ChIP assays were performed with anti-histone H3K4me3, H3K9ac or H3K27ac pAb. The relative intensity (/Input) is shown with the standard deviation. Four independent experiments (A, B and D) were performed with similar results.
doi:10.1371/journal.pone.0061785.g005

2251 is a novel therapeutic candidate for diseases involving allergic inflammation, including asthma.

The generation of IL-13-producing cells and IL-13 production were augmented by SH-2251 treatment *in vitro*. The IL-13 production moderately increased in the *Gfi1*-deficient CD4 T cells (M.Y. unpublished observation), suggesting that Gfi1 may inhibit IL-13 production in CD4 T cells. However, our *in vivo* experimental results demonstrated a reduction in IL-13 production induced by the administration of SH-2251. In addition, the production of IL-4 was also moderately decreased *in vivo*. A DNA microarray analysis indicated a reduced expression of *Ccr3* mRNA in the SH-2251-treated Th2 cells. Therefore, it is likely that SH-2251 exerts some effects on the expressions of chemokine receptors in Th2 cells and that recruitment of Th2 cells to the inflamed sites is inhibited. In addition, it is possible that SH-2251 also affects the function of antigen-presenting cells. Taken together, although an SH-2251-mediated increase in IL-13 production was detected in the *in vitro* experiments, the administration of SH-2251 provides beneficial effects in the treatment of asthmatic patients.

Lung epithelial cells can produce multiple cytokines, including IL-25 and IL-33, in response to various stressors. The intranasal administration of IL-25 induces asthmatic symptoms [36], and anti-IL-25 antibody treatment suppresses OVA-induced allergic inflammation [37]. It is thought that IL-25 acts on NKT cells and promotes Th2 cytokine production [38]. Recently, the IL-33-mediated production of IL-5 has been reported to play a critical role in lung eosinophil regulation [16], lung inflammation [17] and protease allergen-induced airway inflammation [18]. Gfi1, a downstream target of SH-2251, is broadly expressed in hematopoietic lineage cells, and *Gfi1* knockout animals display many abnormalities, including neutropenia, T cell development defects, hematopoietic stem cell defects and defects in dendritic cell

development and functions [20]. It is likely that Gfi1 is also expressed in NKT cells, NH cells, neuocytes and IL-5-producing innate cells. Therefore, it is interesting to examine whether the treatment of SH-2251 can inhibit both the IL-25- and IL-33-induced production from these cell populations.

SH-2251 inhibits the generation of IL-5-producing Th2 cells, in part by repressing Gfi1 induction. Gfi1 is induced by the TCR-mediated activation of the ERK MAPK cascade [25]. In this study, although SH-2251 inhibited the Gfi1 expression, the inhibitory activity for ERK MAPK was very weak ($IC_{50}>1$ μM; M.I. and F.K. personal communication). The activation of the Ras-ERK MAPK cascade also prevents the ubiquitin/proteasome-dependent degradation of Gata3 [39]. The treatment of developing Th2 cells with SH-2251 failed to inhibit the Gata3 protein expression. Therefore, it is unlikely that SH-2251 inhibits IL-5-producing Th2 cell differentiation by suppressing Ras-ERK MAPK cascade activation.

Gfi1 is a DNA binding transcriptional repressor that interacts with a number of histone modification enzymes, including LSD-1/ CoRest [22], G9a [23] and HDACs [21]. However, these histone modification enzymes introduce repressive marks on the histones. We previously demonstrated that Gfi1 is required for induction of active histone marks on the *Il5* gene locus [25]. In addition, the transduction of Gfi1 into SH-2251-treated Th2 cells restored active histone modifications (H3K4me3, H3K9ac and H3K27ac) at the *Il5* gene locus. Although precious molecular mechanisms remain to be elucidated, our data indicate the possible role of Gfi1 in the formation of the active chromatin status.

An increased activity of histone acetyltransferases (HATs) and concomitant reductions in histone deacetylase (HDAC) activity have been reported in asthmatic patients [40] [41]. Changes in these histone modification enzymes result in hyperacetylations of

105

A

B

C

D

E

Figure 6. Transduction of *Gfi1* into SH-2251-treated Th2 cells restores the differentiation of IL-5-producing Th2 cells. (A), CD4 T cells were cultured under Th2-conditions in the presence or absence of SH-2251 (100 nM) for two days, then the cells were transduced with Mock- or *Gfi1*-IRES-hNGFR-containing retrovirus vectors. Three days after transduction, the IL-5/IFN-γ staining profiles of the transduced cells (hNGFR-positive cells) were determined with intracellular staining. The percentages of cells in each quadrant are indicated. **(B)**, The cytokine production from SH-2251-treated Th2 cells transduced with *Gfi1* was determined. **(C)**, Histones H3K4me3, H3K9ac and H3K27ac at the *Il5* gene locus in hNGFR-positive *Gfi1*-transduced SH-2251-treated Th2 cells. The relative intensity (/Input) is shown with the standard deviation. Three (A, B and C) independent experiments were performed with similar results. **(D)**, The global pattern of Gfi1 binding around the *Il5* gene locus was determined using ChIP-sequencing with an anti-Gfi1 mAb. The locations of the PCR primer pairs (triangle) used in a manual ChIP assay are also listed. **(E)**, The binding of Gfi1 around the *Il5* gene locus in SH-2251-treated Th2 cells was determined using a manual ChIP assay. The relative intensity (/Input) is shown with the standard deviation. Two independent experiments were performed with similar results.
doi:10.1371/journal.pone.0061785.g006

histone, opening up the chromatin structure and increasing recruitment of RNA polymerase II [42]. Although the gene locus specific inhibitor for histone acetylation is expected to appear, such molecules have not yet been identified. We demonstrated that SH-2251 selectively inhibits induction of active histone marks, in particular H3K27ac at the *Il5* gene locus and the *Gfi1* gene locus. The transduction of *Gfi1* into SH-2251 treated Th2 cells restores the IL-5 production and active histone modifications at the *Il5* gene locus. These results indicate that SH-2251 belongs to a novel class of inhibitors that modulate histone modification status in a gene locus-specific manner.

In summary, SH-2251 selectively inhibits chromatin remodeling at the *Il5* gene locus and subsequent generation of IL-5-producing Th2 cells via attenuation of the Gfi1 expression. In addition, the oral administration of SH-2251 showed inhibitory effects on

OVA-induced airway allergic inflammation. Therefore, SH-2251 is a unique class of therapeutic candidate for allergic inflammation acting through the selective inhibition of IL-5 production.

Materials and Methods

SH-2251

SH-2251 (United States Patent No.: US 7632865 B2) was synthesized and provided by Ishihara Sangyo Kaisha, Ltd. The purity of the SH-2251 used in the experiments was 99.1%.

Mice

C57BL/6 and BALB/c mice were purchased from CLEA Japan. All mice were maintained under specific pathogen-free conditions and were used at 6–10 weeks of age. All experiments

using mice received approval from the Kazusa DNA Research Institute Administrative Panel for Animal Care. All animal care was conducted in accordance with the guidelines of the Kazusa DNA Research Institute.

CD4 T cells differentiation *in vitro*

Naïve CD4 T (CD44^{lo}CD62L^{hi}) cells were prepared using a CD4$^+$CD62L$^+$ T cell isolation kit II (Miltenyi Biotec). Naïve CD4 T cells (1.5×10^6) were stimulated with an immobilized anti-TCR-β mAb (3 µg/ml; H57-597; BioLegend) and an anti-CD28 mAb (1 µg/ml; 37.5; BioLegend) with or without SH-2251 (Ishihara Sangyo Kaisha, Ltd.) under the indicated culture conditions for two days. Next, the cells were transferred onto a new plate and cultured for an additional three days in the presence of cytokines with or without SH-2251. If not mentioned, 100 nM of SH-2251 was used in the experiments. The cytokine conditions for Th2 cell differentiation were as follows: IL-2 (2.5 ng/ml), IL-4 (10 ng/ml; PeproTech) and anti-IFN-γ mAb (5 µg/ml; R4-6A2; BioLegend).

Intracellular staining of cytokines

The *in vitro* differentiated Th cells were stimulated with an immobilized anti-TCR-β mAb (3 µg/ml; H57-597; BioLegend) for six hours in the presence of monensin (1 µM), and intracellular staining was performed as previously described [25]. The following antibodies were used for intracellular staining: anti-IL-4-hycoerythrin (PE) mAb (11B11; BD Bioscience), IFN-γ-FITC mAb (XMG1.2; BD Bioscience), IL-5-allophycocyanin (APC) (TRFK5; eBioscience), and IL-13-PE (eBio13A; eBioscience). A flow cytometric analysis was performed using a FACSCalibur instrument (BD biosciences), and the results were analyzed using the FlowJo software program (Tree Star).

ELISA

The cells were stimulated with an immobilized anti-TCR-β mAb for 16 hours, and the culture supernatants were recovered. The amount of cytokines in the recovered supernatants was determined with ELISA, as described previously [43].

Quantitative RT-PCR

Total RNA was isolated using a TRIZOL Reagent (GIBCO). cDNA was synthesized using the Superscript VILO cDNA synthesis kit (Invitrogen). Quantitative RT-PCR was performed as previously described [43], using StepOnePlus Real-Time PCR Systems (Applied Biosystems). The specific primers, and Roche Universal Probes used in the experiments were as follows:

Hprt: 5′ TCCTCCTCAGACCGCTTT 3′ (forward), 5′ CCTGTTCATCATCGTAATC 3′ (reverse), probe #95; *Gata3*: 5′ TTATCAAGCCCAAGCGAAG 3′ (forward), TGGTGGTGGTCTGACAGTT 3′ (reverse), probe #108; *Gfi1*: 5′ TCCGAGTTCGAGGACTTTG 3′ (forward), 5′ GAGCGGCACAGTGACTTCT 3′ (reverse), probe #7.

Microarray analysis

The gene expression profiles of the SH-2251-treated Th2 cells were analyzed using the Agilent Whole Mouse 44K Array. The raw data were subjected to log2 transformation and normalized using the Subio Platform (Subio). The gene expression data were deposited in the GSE42131.

Chromatin Immunoprecipitation (ChIP) assay and ChIP-sequencing

The Magna ChIP kit was used for the ChIP assay according to the manufacturer's protocol (MILLIPORE). The anti-histone

H3K4me2 pAb (ab7766; Abcam), anti-histone H3K4me3 pAb (cat#39159; Activemotif), anti-histone H3K27me3 pAb (cat#39155; Activemotif), anti-histone H3K36me3 pAb (ab9050; Abcam), anti-histone H3K9ac pAb (cat#39137; ActiveMotif), anti-histone H3K27ac pAb (cat#39133; ActiveMotif), anti-Gata3 (cat# AF2605; R&D) pAb and anti-Gfi1 (M-19; Santa Cruz) were used for immunoprecipitation. The specific primers at the Th2 cytokine gene locus and the Roche Universal probes used in the experiments were as follows: #1: 5′ ACGCTTCCGGAACTAGGG 3′ (forward), 5′ CGCTCTGGCATCTCGTTC 3′ (reverse), probe #38; #2 (G2): 5′ CAGATGTGATATGCGTACATGTAATTC 3′ (forward), 5′ TGAACTCCTGACCCTGCTTT 3′ (reverse), probe #79; #3: 5′ AGTGTCTGTCCCCCAGATCA 3′ (forward), 5′ GCTGCCTGGAACTTGGTG 3′ (reverse), probe #64; #4: (Il5p), 5′ TCACTTTATCAGGAATTGAGTTTAACA 3′ (forward), 5′ GATCGGCTTTTCTTGAGCA 3′ (reverse), probe #43; #5: 5′ TGCCTCTCTTTGTTTTCCTTG 3′ (forward), 5′ GCAATTCAGTGGTAGAGT

GCTCA 3′ (reverse), probe #81; #6 (G4): 5′ AGTACAAGGGCCAAGTCACG 3′ (forward), 5′ GCCAGAGACTGGGGGTAAGT 3′ (reverse), probe #16; #7: 5′ GCTGGCCTTGAACTTACTACG 3′ (forward), 5′ GTGTGTACCCGTAATCCCA

AC 3′ (reverse), probe #10; G1: 5′ GGAAGTGGGAGTCCTAAGCA 3′ (forward), 5′ CTCCCTGCCCAACTTCTAAA 3′ (reverse), probe #15; G3: 5′ AAGGGGAGAACTGCCTCCTA 3′ (forward), 5′ TCATGCCATGGGATACAGG (reverse), prove #99; Il4p: 5′ TTGGTCTGATTTCACAGGAAAA 3′ (forward), 5′ GGCCAATCAGCACCTCTCT 3′ (reverse), probe #2; V$_A$ site in the IL-4 enhancer: 5′ GCCTGTTTCCTCTCAGCATT 3′ (forward), 5′ TGATAAAAGTGACTTGAAGGTT

GG 3′ (reverse), probe #4; IL-4 intronic enhancer: 5′ CCCAAAGGAGGTGCTTTT

ATC 3′ (forward), 5′ AAATCCGAAACTGAGGAGTGC 3′ (reverse), probe #75; Il13p: 5′ CCAGGTTCTGGGTGGTTTATT 3′ (forward), 5′ GAATTACTGGGGCGGAAGTT 3′ (reverse), probe #105; Rad50p: 5′ GGAAGTGGGAGTCCTAAGCA 3′ (forward), 5′ CTCCCTGCCCAACTTCTAAA 3′ (reverse), probe #15. The specific primers at the Gfi1 gene locus and the Roche Universal probes used in the experiments were as follows:

a: 5′ TTTGCAGAAGAGTGAGGTTTGA 3′ (forward), 5′ TGGAGGCGTGGGATTAAC 3′ (reverse), probe #55; b: 5′ GACCAAGGCGTGTGA

CTATACA 3′ (forward), 5′ CACACCCTGTTGTACCCACTT 3′ (reverse), probe #48; c: 5′ GTGCCACACCACTATTCCAG 3′ (forward), 5′ AGTGGCAAAGGACCAAC

ACT 3′ (reverse), probe #2; d: 5′ TGGGGACAGGTTTACCACT 3′ (forward), 5′ GACAGGTGGCACGAATCC 3′ (reverse), probe #70.

The samples for the ChIP-sequencing were prepared according to the manufacturer's protocol (Illumina), and the ChIP-sequence was performed using Genome Analyzer IIx (Illumina).

Immunoblot analysis

Cytoplasmic and nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Regents (Thermo Fisher Scientific) as previously described [43]. Anti-Gata3 mAb (HG3-31; Santa Cruz), anti-Gfi1 pAb (M-19; Santa Cruz) and anti-α-Tubulin mAb (DM1A; Lab Vision) were used for the immunoblot analysis.

Retrovirus-mediated gene transfer

The methods for generating retrovirus supernatant and infection were described previously [25]. Infected cells were detected using staining with anti-human NGFR-PE mAb (ME20.4-1.H4; Miltenyi Biotec) and anti-PE microbeads (#130-048-801; Miltenyi Biotec), and hNGFR-positive infected cells were purified using AutoMACS (Miltenyi Biotec).

Luciferase assay

The IL-5 promoter activity was determined as previously described [30]. In brief, M12 cells (B cell line) were cotransfected with a firefly luciferase reporter (pGL3-*Il5* promoter), a renila luciferase plasmid (pRL-TK; Promega) and an expression vector (pFlag-CMV2; Sigma) using Gene Pulser MXcell (BIO-RAD). Twenty-four hours after transfection, the cells were maintained in the presence or absence of SH-2251 for one hour, and then stimulated with PMA plus dibuteryl-cAMP for 12 hours. The luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega).

OVA-induced allergic airway inflammation

BALB/c mice were immunized intraperitoneally with 100 μg OVA in 2 mg of aluminum hydroxide gel on day 0. Next, the mice were intranasally challenged with OVA in saline (100 μg/mouse) on days 8 and 10. SH-2251 (10 mg/kg) was orally administered every day from day 0 to day 11. Two days after the last OVA challenge, BAL fluid cells and lung samples were prepared for histological examination as previously described [44]. Lung mononuclear cells were also prepared two days after the last OVA challenge, as previously described [45]. CD4 T cells were purified from lung mononuclear cells using anti-mouse CD4 microbeads (Miltenyi Biotec).

Statistical analysis

Student's *t*-test was used for the statistical analyses. ANOVA and the Bonferroni-test were used in the *in vivo* experiments.

Supporting Information

File S1 The effects of SH-2251 on Th1-, Th9-, and Th17-differentiation. Naïve CD4 T cells were cultured under Th1- (A), Th9- (B) or Th17- (C) conditions in the presence or absence of SH-2251 (100 nM) for five days. The cells were restimulated with an immobilized anti-TCR-β mAb for six hours, and the intracellular staining profiles were determined using intracellular staining (left). The following antibodies were used for intracellular staining: anti-IL-4-PE mAb (11B11; BD Bioscience), IFN-γ-FITC mAb (XMG1.2; BD Bioscience), anti-IL-9-PE mAb (RM9A4; BioLegend), anti-IL-17A-Alexa647 mAb (TC11-18H10.1; BioLegend) and IL-17F-Alexa488 mAb (9D3.1C8; BioLegend). The percentages of each quadrant are indicated. The cytokine production by the SH-2251-treated Th cells stimulated with an immobilized anti-TCR-β mAb for 16 hours was determined with ELISA. The culture conditions for each Th cell differentiations were as follows. Th1-conditions: IL-2 (2.5 ng/ml), IL-12 (1 ng/ml; PeproTech) and anti-IL-4 mAb (5 μg/ml; 11B11; BioLegend). Th9-conditions: IL-2 (2.5 ng/ml), IL-4 (10 ng/ml), TGF-β (10 ng/ml; PeproTech) and anti-IFN-γ mAb (5 μg/ml). The Th17-conditions were as follows: IL-6 (10 ng/ml; PeproTech), IL-1β (5 ng/ml; PeproTech), TGF-β (1 ng/ml), anti-IL-2 (5 μg/ml; BioLegend), anti-IL-4 mAb (5 μg/ml) and anti-IFN-γ mAb. Three independent experiments were performed with similar results. *$P<0.05$ and **$P<0.01$ (Student's *t*-test).
(DOCX)

Acknowledgments

Author Contributions

Conceived and designed the experiments: JS MY. Performed the experiments: JS MK ST TN OO MY. Analyzed the data: JS MK. Contributed reagents/materials/analysis tools: MI FK. Wrote the paper: JS MY.

References

1. Adcock IM, Caramori G, Chung KF (2008) New targets for drug development in asthma. Lancet 372: 1073–1087.
2. Holgate ST (2008) Pathogenesis of asthma. Clin Exp Allergy 38: 872–897.
3. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM (2011) Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res 12: 114.
4. Kouro T, Takatsu K (2009) IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 21: 1303–1309.
5. Rothenberg ME, Hogan SP (2006) The eosinophil. Annu Rev Immunol 24: 147–174.
6. Gauvreau GM, Ellis AK, Denburg JA (2009) Haemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 39: 1297–1306.
7. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG (1996) Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183: 195–201.
8. Wei L, Vahedi G, Sun HW, Watford WT, Takatori H, et al. (2010) Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity 32: 840–851.
9. Ansel KM, Djuretic I, Tanasa B, Rao A (2006) Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol 24: 607–656.
10. Wilson CB, Rowell E, Sekimata M (2009) Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9: 91–105.
11. Nakayama T, Yamashita M (2008) Initiation and maintenance of Th2 cell identity. Curr Opin Immunol 20: 265–271.
12. Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28: 445–489.
13. Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H (2010) The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 22: 1–6.
14. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, et al. (2010) Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367–1370.
15. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, et al. (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463: 540–544.
16. Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, et al. (2012) Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol 188: 703–713.
17. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, et al. (2012) IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 188: 1503–1513.
18. Halim TY, Krauss RH, Sun AC, Takei F (2012) Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36: 451–463.
19. Poon AH, Eidelman DH, Martin JG, Laprise C, Hamid Q (2012) Pathogenesis of severe asthma. Clin Exp Allergy 42: 625–637.
20. Moroy T, Khandanpour C (2011) Growth factor independence 1 (Gfi1) as a regulator of lymphocyte development and activation. Semin Immunol 23: 368–378.
21. Montoya-Durango DE, Velu CS, Kazanjian A, Rojas ME, Jay CM, et al. (2008) Ajuba functions as a histone deacetylase-dependent co-repressor for autoregulation of the growth factor-independent-1 transcription factor. J Biol Chem 283: 32056–32065.
22. Saleque S, Kim J, Rooke HM, Orkin SH (2007) Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell 27: 562–572.
23. Duan Z, Zarebski A, Montoya-Durango D, Grimes HL, Horwitz M (2005) Gfi1 coordinates epigenetic repression of p21Cip/WAF1 by recruitment of histone

lysine methyltransferase G9a and histone deacetylase 1. Mol Cell Biol 25: 10338–10351.

24. Zhu J, Guo L, Min B, Watson CJ, Hu-Li J, et al. (2002) Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity 16: 733–744.

25. Shinnakasu R, Yamashita M, Kuwahara M, Hosokawa H, Hasegawa A, et al. (2008) Gfi1-mediated stabilization of GATA3 protein is required for Th2 cell differentiation. J Biol Chem 283: 28216–28225.

26. Northrup DL, Zhao K (2011) Application of ChIP-Seq and related techniques to the study of immune function. Immunity 34: 830–842.

27. Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21: 381–395.

28. Agarwal S, Avni O, Rao A (2000) Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo. Immunity 12: 643–652.

29. Tanaka S, Motomura Y, Suzuki Y, Yagi R, Inoue H, et al. (2011) The enhancer HS2 critically regulates GATA-3-mediated Il4 transcription in T(H)2 cells. Nat Immunol 12: 77–85.

30. Yamashita M, Ukai-Tadenuma M, Kimura M, Omori M, Inami M, et al. (2002) Identification of a conserved GATA3 response element upstream proximal from the interleukin-13 gene locus. J Biol Chem 277: 42399–42408.

31. Lee GR, Spilianakis CG, Flavell RA (2005) Hypersensitive site 7 of the TH2 locus control region is essential for expressing TH2 cytokine genes and for long-range intrachromosomal interactions. Nat Immunol 6: 42–48.

32. Lee GR, Fields PE, Griffin TJ, Flavell RA (2003) Regulation of the Th2 cytokine locus by a locus control region. Immunity 19: 145–153.

33. Schwenger GT, Fournier R, Kok CC, Mordvinov VA, Yeoman D, et al. (2001) GATA-3 has dual regulatory functions in human interleukin-5 transcription. J Biol Chem 276: 48502–48509.

34. Abonia JP, Putnam PE (2011) Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol 7: 411–417.

35. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, et al. (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360: 973–984.

36. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, et al. (2002) New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 169: 443–453.

37. Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, et al. (2007) Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 120: 1324–1331.

38. Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, et al. (2008) A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med 205: 2727–2733.

39. Yamashita M, Shinnakasu R, Asou H, Kimura M, Hasegawa A, et al. (2005) Ras-ERK MAPK cascade regulates GATA3 stability and Th2 differentiation through ubiquitin-proteasome pathway. J Biol Chem 280: 29409–29419.

40. Ito K, Caramori G, Lim S, Oates T, Chung KF, et al. (2002) Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 166: 392–396.

41. Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, et al. (2004) Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 170: 141–147.

42. Khan AU, Krishnamurthy S (2005) Histone modifications as key regulators of transcription. Front Biosci 10: 866–872.

43. Kuwahara M, Yamashita M, Shinoda K, Tofukuji S, Onodera A, et al. (2012) The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-beta and suppresses T(H)2 differentiation. Nat Immunol 13: 778–786.

44. Yamashita M, Kuwahara M, Suzuki A, Hirahara K, Shinnaksu R, et al. (2008) Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J Exp Med 205: 1109–1120.

45. Suzuki A, Iwamura C, Shinoda K, Tumes DJ, Kimura MY, et al. (2010) Polycomb group gene product Ring1B regulates Th2-driven airway inflammation through the inhibition of Bim-mediated apoptosis of effector Th2 cells in the lung. J Immunol 184: 4510–4520.

109

Exome sequencing identifies secondary mutations of *SETBP1* and *JAK3* in juvenile myelomonocytic leukemia

Hirotoshi Sakaguchi[1,8], Yusuke Okuno[2,8], Hideki Muramatsu[1,8], Kenichi Yoshida[2,8], Yuichi Shiraishi[3], Mariko Takahashi[2], Ayana Kon[2], Masashi Sanada[2,4], Kenichi Chiba[3], Hiroko Tanaka[5], Hideki Makishima[6], Xinan Wang[1], Yinyan Xu[1], Sayoko Doisaki[1], Asahito Hama[1], Koji Nakanishi[1], Yoshiyuki Takahashi[1], Nao Yoshida[7], Jaroslaw P Maciejewski[6], Satoru Miyano[3,5], Seishi Ogawa[2,4,9] & Seiji Kojima[1,9]

Juvenile myelomonocytic leukemia (JMML) is an intractable pediatric leukemia with poor prognosis[1] whose molecular pathogenesis is poorly understood, except for somatic or germline mutations of RAS pathway genes, including *PTPN11*, *NF1*, *NRAS*, *KRAS* and *CBL*, in the majority of cases[2–4]. To obtain a complete registry of gene mutations in JMML, whole-exome sequencing was performed for paired tumor-normal DNA from 13 individuals with JMML (cases), which was followed by deep sequencing of 8 target genes in 92 tumor samples. JMML was characterized by a paucity of gene mutations (0.85 non-silent mutations per sample) with somatic or germline RAS pathway involvement in 82 cases (89%). The *SETBP1* and *JAK3* genes were among common targets for secondary mutations. Mutations in the latter were often subclonal and may be involved in the progression rather than the initiation of leukemia, and these mutations associated with poor clinical outcome. Our findings provide new insights into the pathogenesis and progression of JMML.

JMML is a rare myelodysplastic/myeloproliferative neoplasm unique to childhood, characterized by excessive proliferation of myelomono-cytic cells and hypersensitivity to granulocyte-macrophage colony-stimulating factor[1]. A cardinal genetic feature of JMML is frequent somatic and/or germline mutation of RAS pathway genes, such as *NF1*, *NRAS*, *KRAS*, *PTPN11* and *CBL*, which are mutated in more than 70% of JMML cases in a mutually exclusive manner[2–4]. However, it is still open to question whether RAS pathway mutations are sufficient for the development of JMML or if secondary mutations have a role in the development and progression of this cancer. To address these issues and to better define the molecular pathogenesis of JMML, we performed whole-exome sequencing of paired tumor-normal DNA from 13 cases (**Supplementary Table 1**). We obtained mean coverage

in exome sequencing of 137× for tumor samples and 143× for normal samples (**Supplementary Fig. 1**). A Monte-Carlo simulation indicated that the study detected 88% of the existing somatic mutations (Online Methods and **Supplementary Fig. 2**).

Sanger sequencing of 25 candidate non-silent somatic nucleotide alterations confirmed 1 nonsense and 10 missense mutations (**Table 1** and **Supplementary Fig. 3**), with the low true positive rate consistent with the very low numbers of somatic mutations in JMML. Of the 11 somatic mutations, 6 involved known RAS pathway genes. In addition, non-overlapping RAS pathway mutations (6 somatic and 6 germline) were confirmed in 11 of the 13 discovery cases (86%; **Table 1**). For the remaining two cases that lacked documented RAS pathway mutations, we intensively searched for possible germline mutations that could be relevant to the development of JMML. In total, 179 and 167 candidate germline mutations were detected in subjects 77 and 92, respectively, but these mutations did not affect known RAS pathway genes or other cancer-related genes, including the ones registered in the pathway databases (Online Methods). A frameshift deletion in *KMT2D* (also known as *MLL2*; encoding p.Val1670fs) was found in subject 92, who had been diagnosed as having Noonan syndrome on the basis of typical features such as hypertelorism, webbed neck and congenital heart disease (**Supplementary Fig. 3**) but lacked the distinctive facial appearance of Kabuki syndrome, which was shown to be caused by germline *KMT2D* mutations[5].

Five of the 11 somatic mutations were non–RAS pathway mutations, involving *SETBP1* (3 p.Asp868Asn alterations), *JAK3* (1 p.Arg657Gln alteration) and *SH3BP1* (1 p.Ser277Leu alteration), which had not been reported in JMML cases. SETBP1 was originally isolated as a 170-kDa nuclear protein that interacts with SET, a small protein inhibitor of the putative tumor suppressors PP2A and NM23-H1 (ref. 6). Several lines of recent evidence suggest that SETBP1 has a role in leukemogenesis (**Supplementary Fig. 4**)[7–11]. *SETBP1* participates in

[1]Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan. [2]Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [3]Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. [4]Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. [5]Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. [6]Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA. [7]Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan. [8]These authors contributed equally to this work. [9]These authors jointly directed this work. Correspondence should be addressed to S.O. (sogawa-tky@umin.ac.jp) or S.K. (kojimas@med.nagoya-u.ac.jp).

Table 1 List of gene mutations identified by whole-exome sequencing

Subject number	RAS pathway mutations								Other somatic mutations			
	Somatic				Germline							
	Gene	Change at DNA level	Change at protein level	VAF[a]	Gene	Change at DNA level	Change at protein level	VAF[a]	Gene	Change at DNA level	Change at protein level	VAF[a]
11[b]	NF1	c.4537C>T	p.Arg1513*	40.1/24.2	NF1	c.5927delG	p.Trp1976fs	44.0/47.1	SETBP1	c.2602G>A	p.Asp868Asn	32.6/27.0
63	KRAS	c.38G>A	p.Gly13Asp	44.3/0.0	–	–	–	–	–	–	–	–
72	PTPN11	c.172A>T	p.Asn58Tyr	48.2/5.7	–	–	–	–	SETBP1	c.2602G>A	p.Asp868Asn	45.9/2.5
									JAK3	c.1970G>A	p.Arg657Gln	30.5/2.2
									SH3BP1	c.830C>T	p.Ser277Leu	47.8/5.1
77	–	–	–	–	–	–	–	–	SETBP1	c.2602G>A	p.Asp868Asn	33.4/2.1
78	NRAS	c.35G>C	p.Gly12Ala	45.5/9.5	–	–	–	–	–	–	–	–
82	–	–	–	–	CBL	c.1217del22	p.Thr406fs	34.7/38.9	–	–	–	–
83	–	–	–	–	NF1	c.4970A>G	p.Tyr1657Cys	50.0/51.0	–	–	–	–
84	–	–	–	–	CBL	c.1096–110del643	p.Glu366_Phe488del	NA/NA	–	–	–	–
85	PTPN11	c.226G>A	p.Glu76Lys	47.5/4.4	–	–	–	–	–	–	–	–
86	KRAS	c.38G>A	p.Gly13Asp	38.9/3.1	–	–	–	–	–	–	–	–
89[c]	–	–	–	–	PTPN11	c.1502T>G	p.Ser502Ala	50.0/49.9	–	–	–	–
91[c]	–	–	–	–	PTPN11	c.218C>T	p.Thr73Ile	49.0/48.0	–	–	–	–
92[c]	–	–	–	–	–	–	–	–	–	–	–	–

NA, not available.
[a]Variant allele frequency (VAF) in tumor/reference samples, where the reference was CD3+ T cells, except for subject 63, for whom umbilical cord was used as the reference. [b]Substantial contamination of tumor cell components in the CD3+ T cell reference. [c]Noonan syndrome–associated myeloproliferative disorder.

translocations that result in an aberrant fusion gene (*NUP98-SETBP1*) and overexpression of *SETBP1* in T cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML), respectively[12,13].

SETBP1 is one of the downstream targets induced by the Evi-1 onco-protein[14] and, together with *EVI1* and its homolog *PRDM16* (also known as *MEL1*), was reported to be activated through retrovirus integration. SETBP1 is also known to augment the recovery of granulopoiesis after gene therapies for chronic granulomatous disease[15]. *SETBP1* overexpression is found in more than 27% of adult AML cases and is associated with poor survival[13]. The discovery of recurrent hotspot mutations of *SETBP1* provides unequivocal evidence for the leukemogenic role of deregulated SETBP1 function. Notably, the *SETBP1* mutation encoding p.Asp868Asn was identical to one of the de novo mutations reported to be causative in Schinzel-Giedion syndrome (SGS; MIM 269150), which is a highly recognizable congenital disease characterized by severe mental retardation, distinctive facial features and


Figure 1 Mutation profiles of 92 JMML cases. (a) The mutation status of RAS pathway genes and 2 newly identified gene targets in a cohort of 92 JMML cases is summarized. NS/MPD, Noonan syndrome–associated myeloproliferative disorder. (b) The distribution of alterations is shown for each protein. SH2, Src homology 2 domain; PTPc, protein tyrosine phosphatase, catalytic domain; RAS, Ras GTPase family domain; TKB, tyrosine kinase–binding domain; RING, RING-finger domain; UBA, ubiquitin-associated domain; RasGAP, a region of similarity with the catalytic domain of the mammalian p120RasGAP protein in neurofibromin; SEC14, Sec14p-like lipid-binding domain; SKI, v-ski sarcoma viral oncogene homolog domain; SETBD, SET-binding domain; PTK, pseudokinase domain of the protein tyrosine kinases.

111

Table 2 Subject characteristics

| Characteristic | Total cohort (n = 92) | Secondary mutations | | P value |
		Yes (n = 16)	No (n = 76)	
Sex (male/female)	61/31	12/4	49/27	NS
Median age at diagnosis in months (range)	19 (1–160)	38 (2–160)	13 (1–79)	<0.001
Diagnosis				
JMML	85	16	69	
NS/MPD	7	0	7	
Genetic mutations in RAS pathway				
PTPN11	39	9	30	NS
NF1	9	5	4	0.001
RAS (NRAS or KRAS)	28 (15/13)	2 (1/1)	26 (14/12)	0.08
CBL	14	0	14	0.06
Without RAS pathway mutation	10	1	9	NS
Secondary genetic mutations				
SETBP1	7	7	0	
JAK3	10	10	0	
Cytogenetics				
Normal karyotype	77	12	65	NS
Monosomy 7	8	1	7	NS
Trisomy 8	4	2	2	NS
Other abnormalities	3	1	2	NS
WBC count at diagnosis $\times 10^9$/l, median (range)	30.0 (1.0–563)	29.6 (5.6–563)	30.0 (1.0–131)	NS
Monocyte count at diagnosis $\times 10^9$/l, median (range)	4.6 (0.2–31.6)	3.1 (0.5–15.2)	4.9 (0.2–31.6)	NS
Percent HbF at diagnosis, median (range)	21 (0–68)	26 (9–55)	16 (0–68)	NS
PLT at diagnosis $\times 10^9$/l, median (range)	61.0 (1.4–483)	47.5 (1.4–175)	65.0 (5.0–483)	NS
HSCT (+/–)	56/36	16/0	40/36	
Alive/deceased	62/30	7/9	55/21	
Percent probability of 5-year overall survival (95% CI)	60 (46–71)	33 (10–59)	65 (49–77)	0.10
Percent probability of 5-year transplantation-free survival (95% CI)	15 (6–27)	0 (0–0)	18 (8–33)	0.007

JMML, juvenile myelomonocytic leukemia; NS/MPD, Noonan syndrome–associated myeloproliferative disorder; WBC, white blood cell; HbF, hemoglobin F; HSCT, hematopoietic stem cell transplantation; NS, not significant. We compared the difference between the subjects with and without secondary mutation, and P values were calculated by two-sided Fisher's exact test or Mann-Whitney U test.

multiple congenital malformations. Individuals with SGS with this mutation have a higher than normal prevalence of tumors, including of neuroepithelial neoplasia[16], although development of myeloid malignancies has not been reported so far.

To further validate our findings, we screened the entire cohort of 92 JMML cases for gene mutations in the newly identified 3 genes

together with known RAS pathway targets using deep sequencing[17] (Supplementary Fig. 5).

RAS pathway mutations were found in 82 of 92 cases (89%) in a mutually exclusive manner, with PTPN11 mutations predominant, followed by NRAS, KRAS, CBL and NF1 mutations (Fig. 1a and Table 2). In accordance with previous reports, most of the CBL (8/14) and NF1 (4/9) mutations were biallelic (Fig. 1a,b and Supplementary Table 2)[2,3,18], whereas the majority of mutations in PTPN11, NRAS and KRAS were heterozygous[4]. The individuals without RAS pathway mutations (n = 10) were vigorously investigated by whole-genome sequencing of tumor-normal paired samples (n = 2; Supplementary Fig. 6) or by whole-exome sequencing of only tumor samples (n = 8; Supplementary Fig. 7). As anticipated, we found no known RAS pathway mutations.

On the other hand, 18 mutations were found in SETBP1 (n = 7) or JAK3 (n = 11) in 16 cases (Fig. 1a,b, Table 2 and Supplementary Table 2), with these mutations more frequent in cases with mutated PTPN11 (and possibly NF1) than in cases with mutated NRAS, KRAS

a

SETBP1 and JAK3 (n = 1)　SETBP1 (n = 5)　SETBP1 (n = 1)　JAK3 (n = 1)

JAK3 (n = 8)
No secondary mutation (n = 32)
No secondary mutation (n = 44)

PTPN11 or NF1 (n = 46)　Others (n = 46)

P = 0.001

b

SETBP1 and JAK3 (n = 1)　SETBP1 (n = 6)

JAK3 (n = 9)
No secondary mutation (n = 26)
No secondary mutation (n = 50)

Subjects who survived without HSCT (n = 26)　Other subjects (n = 66)

P = 0.007

c

Overall survival (%)

P = 0.10

No secondary mutation (n = 76)

Secondary mutation (n = 16)

0　100　200　300
Months after diagnosis

d

Transplantation-free survival (%)

P = 0.007

No secondary mutation (n = 76)

Secondary mutation (n = 16)

0　50　100　150
Months after diagnosis

Figure 2 Clinical features of JMML cases with or without secondary mutations. (a,b) Frequency of secondary mutations in individuals with JMML depending on the type of RAS pathway mutations (left, PTPN11 or NF1; right, other or no mutations) (a) and the status of HSCT (b). P values were calculated by two-sided Fisher's exact test. (c,d) The impact of secondary mutations on overall (c) and transplantation-free (d) survival is shown in Kaplan-Meier survival curves, where statistical significance was tested by log-rank test.

112

or *CBL* (**Fig. 2a**). Mutations in *SH3BP1*, encoding SH3 domain–binding protein 1, were not recurrent. All *SETBP1* mutations were heterozygous and occurred within the portion of the gene encoding the SKI domain, with six identical to the *de novo* recurrent mutations reported in SGS and five identical to the mutation encoding the p.Asp868Asn alteration (**Fig. 1b**). RT-PCR analysis showed that the wild-type and mutant alleles of *SETBP1* were equally expressed (**Supplementary Fig. 8**). Similarly, 8 of the 11 *JAK3* mutations in 10 cases were the well-described activating mutation (encoding a p.Arg657Gln alteration) found in various hematological malignancies, including Down syndrome–associated acute megakaryoblastic leukemia[19–23], ALL[24,25] and natural killer (NK)/T cell lymphoma[26], and the remaining 3 were also within the portions of the gene encoding the pseudokinase or kinase domain, suggestive of gain of function.

Deep sequencing of the relevant mutant alleles enabled an accurate estimation of allele frequencies for individual mutations (**Supplementary Fig. 9**). *SETBP1* and *JAK3* mutations showed lower allele frequencies (but not with statistical significance for *SETBP1*) than did the corresponding RAS pathway mutations (**Supplementary Fig. 10a**), indicating that the former mutations represent secondary genetic hits that contributed to clonal evolution after the main tumor population was established (**Supplementary Fig. 10b**). Individuals with secondary mutations had shorter lengths of survival compared to those without mutations: 5-year overall survival (hazards ratio (HR) = 1.90, 95% CI = 0.87–4.19). In addition, none of the individuals with JMML who survived without hematopoietic stem cell transplantation (HSCT; *n* = 26) harbored any of the secondary mutations, and individuals with secondary mutations showed significantly inferior 5-year transplant-free survival (HR = 2.18, 95% CI = 1.18–4.02) (**Fig. 2b–d** and **Table 2**).

JMML is characterized by a paucity of gene mutations. The average number of mutations per sample (0.85; range of 0–4) was unexpectedly low compared to those reported in other human cancers (**Supplementary Fig. 11**); excluding common RAS pathway mutations, only 5 mutations were detected in 3 of the 13 discovery cases. This small number of mutations is only comparable to the figure reported for retinoblastoma (mean of 3.3 per case; range of 0–5) (ref. 27) and is in stark contrast to the abundance of gene mutations in chronic myelomonocytic leukemia (CMML) in adult cases, where the mean number of non-silent mutations was 12.4 per sample, of which 3.1 represented known driver changes (ref. 17 and K.Y., M.S., Y.S., D. Nowak, Y. Nagata *et al.*, unpublished data), underscoring the distinct pathogenesis in these two neoplasms that show indistinguishable morphology. The impact of germline events is underscored by the fact that 6 of the 13 discovery cases harbored germline RAS pathway mutations and an additional case without known RAS pathway mutations showed constitutive abnormalities similar to Noonan syndrome. Despite the central role of RAS pathway mutations, a small subset of cases had no documented RAS pathway mutations, even after whole-exome analysis in the two RAS pathway mutation–negative cases, raising the possibility that the latter cases represent a genetically distinct myeloproliferative neoplasm in childhood.

Another key finding in the current study is the discovery of secondary mutations that involve *SETBP1* and *JAK3*. Detected only in a subpopulation of leukemic cells, most of these mutations are thought to be involved in the progression rather than the establishment of JMML and were associated with poor clinical outcome. *SETBP1* is a newly identified proto-oncogene, and identical mutations in this gene have recently been reported in 15–25% of adult cases with atypical chronic myeloid leukemia (CML)[10], CMML and secondary

AML[28]. Affecting one of three highly conserved amino acid positions, *SETBP1* mutations have been shown to abolish the binding of an E3 ubiquitin ligase (β-TrCP1) to SETBP1, which prevents ubiquitination and subsequent degradation, leading to gain of function through the consequent increase in SETBP1 protein amounts[10,28]. Although the precise leukemogenic mechanisms of *SETBP1* mutations are still unclear, we have shown that mutant *SETBP1* alleles confer self-renewal capability to myeloid progenitors *in vitro*, and *SETBP1* mutations in adult leukemia were associated with increases in *HOXA9* and *HOXA10* expression[28]. Recurrent *JAK3* mutations in JMML are also noteworthy. The JAK-STAT pathway is a key component of normal hematopoiesis[29]. As in other hematopoietic malignancies[20], the p.Arg657Gln alteration represents the most frequent change in JMML. This alteration confers interleukin (IL)-3 independence to Ba/F3 cells and induces STAT5 phosphorylation[20]. Targeting the JAK-STAT pathway with a pan-JAK inhibitor such as CP-690550 (ref. 30) could be a promising therapeutic possibility for patients with *JAK3*-mutated JMML.

In conclusion, our whole-exome sequencing analysis identified the spectrum of gene mutations in JMML. Together with the high frequency of RAS pathway mutations, the paucity of non–RAS pathway mutations is a prominent feature of JMML. Mutations of *SETBP1* and *JAK3* were common recurrent secondary events presumed to be involved in tumor progression and were associated with poor clinical outcomes. Our findings provide an important clue to understanding the pathogenesis of JMML that may help in the development of novel diagnostics and therapeutics for this leukemia.

URLs. Genomon, http://genomon.hgc.jp/exome/en/; BioCarta, http://www.biocarta.com/; dbSNP131, http://www.ncbi.nlm.nih.gov/projects/SNP/; RefSeq database, http://www.ncbi.nlm.nih.gov/RefSeq/.

METHODS

Methods and any associated references are available in the online version of the paper.

Accession code. We deposited whole-genome and whole-exome sequence data in the European Genome-phenome Archive under accession EGAS00001000521.

Note: Supplementary information is available in the online version of the paper.

AUTHOR CONTRIBUTIONS
H.S., Y.O., H. Muramatsu, K.Y., M.T., A.K. and M.S. designed and performed the research, analyzed the data and wrote the manuscript. Y.S., K.C., H.T. and S.M. performed bioinformatics analyses of the resequencing data. X.W. and Y.X. performed Sanger sequencing. S.D., A.H., K.N., Y.T. and N.Y. collected specimens and performed the research. H. Makishima and J.P.M. designed the research and analyzed the data. S.O. and S.K. led the entire project and wrote the manuscript.